Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Virtu Financial Inc. Class A Common Stock (VIRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Virtu Financial Inc. Class A Common Stock — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Virtu Financial Inc. Class A Common Stock trades at $55.56 (market cap $4.94B). The key difference: Travere Therapeutics Inc. Common Stock and Virtu Financial Inc. Class A Common Stock are close in size by market cap, and Virtu Financial Inc. Class A Common Stock pays a 1.72% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Virtu Financial Inc. Class A Common Stock for 6 Days on average.
| TVTX | VIRT | |
|---|---|---|
Market Cap | $4.88B | $4.94B |
Volume | 1,668,577 | 1,546,091 |
Sector | Health | Financials |
52-Week High | $67.52 | $67.93 |
52-Week Low | $26.79 | $32.53 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $14.65B |
Dividend Yield | — | 1.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VIRT trades at $55.94, down 1.46% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 9.29, net income margin of 13.5%, and ROE of 31.65%. Recent expansion into Saudi Exchange block trading and consistent earnings outperformance support growth prospects. Analyst consensus price target is $63.00 with mixed ratings (38% buy, 46% hold).
VIRT presents a value opportunity with attractive valuation metrics and strong profitability, though technical indicators suggest near-term pressure. The company's market-making business demonstrates resilience with improving cash flow trends. Key risks include market volatility sensitivity and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Virtu Financial Inc. Class A Common Stock
Virtu Financial provides technology-enabled market-making and execution services. Its platforms help institutional, retail, and other market participants trade across global financial markets.
Read more on VIRT →
